Lilly enters psychedelic realm through $2.8bn AtaiBeckley takeover
This acquisition marks Lilly’s first move into the psychedelic space as the pharma curates a diversified pipeline.
This acquisition marks Lilly’s first move into the psychedelic space as the pharma curates a diversified pipeline.
With 89% of AI pilots failing to scale, biopharmas can move from data skepticism to advocacy by building a trusted, globally harmonized foundation. By Sebastian Wurst, Director of OpenData Strategy,...
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Keeping pace with generative AI in pharmaceutical and healthcare organisations
Pharma Meets AI Conference 2026: Key barriers to scaling AI in drug development
Advancing pressure protection in biopharma: how integrated bypass technology elevates single-use pump design
CinnaGen Enters EU Market with EMA Approval for Zandoriah®